PROJECT

Projects

Environmental & Social Review Summary

Project Number

46047

Company Name

EUROFARMA LABORATORIOS S/A

Date ESRS Disclosed

Sep 12, 2022

Country

Brazil

Region

Latin America and the Caribbean

Last Updated Date

Oct 29, 2022

Environmental Category

B - Limited

Status

Active

Previous Events

Approved : Jun 24, 2022
Signed : Aug 30, 2022
Invested : Oct 25, 2022

Sector

other

Industry

other

Department

Regional Industry MAS LAC & EUR

Project Description

 The proposed investment consists of $100 million loan to Laboratórios Eurofarma S.A. (“Eurofarma” or the “Company”), which is focused on the development, manufacturing, and commercialization of pharmaceutical products for human and animal use. The Company is the main operating entity of Grupo Eurofarma, a leading pharmaceutical group in Brazil.  Eurofarma is headquartered in Sao Paulo, where it also has 3 manufacturing facilities, 2 distribution centers and one research and development facility. Additionally, the Group has 7 manufacturing plants located in Latin America (in Argentina, Chile, Colombia, Peru, Uruguay, and Guatemala).

 

The investment is to support Eurofarma; i) to fund construction of a greenfield pharmaceutical manufacturing plant in Montes Claros, Brazil to produce oral solids and antibiotics; and (ii) increase manufacturing capacity related to fill and finish capacity for the production of the Pfizer COVID-19 vaccine in Brazil.

 

The Montes Claros facility is currently under construction and occupies an area of 20.5 ha and located within an area zoned industrial within the Montes Claros municipality. The facility is expected to commence operations in January 2024.

Overview of IFC's Scope of Review

 IFC’s environmental and social (“E&S”) appraisal included meetings with Eurofarma representatives responsible for Human Resources (HR), the Sustainability Manager and Environmental, Health and Safety (EHS) officers at the corporate level from April 29- May 6, 2022. IFC also visited a Eurofarma facility (Itapevi, one of the larger facilities and where the Pfizer vaccine manufacturing process occurs) in Sao Paulo on May 4, 2022 and conducted interviews with workers and salesforce management on May 10 – 12, 2022.

 

IFC also reviewed procedures and plans related to E&S management at the corporate and facility level allied to organizational capacity in support of Eurofarma’s E&S practices.  This included procedures associated with life and fire safety (LFS) and emergency response, pollution prevention, resource use and solid / liquid waste management.  Occupational health and safety practices (OHS) were also reviewed, along with stakeholder engagement and security management. IFC also commissioned an external consultant (ERGON) specialized in HR to undertake an assessment of labor and working conditions, including interviews and focus groups conversations with salesforces and union representatives. Compliance with applicable E&S national law was also reviewed including relevant permits and licenses related to construction and operational activities. 

 

The appraisal also included review of media reports and other relevant information necessary to understand the contextual risks associated with the Project.   

 

E & S Project Categorization and Applicable Standard

Environmental and Social Mitigation Measures

Stakeholder Engagement

Broad Community Support

Environmental & Social Action Plan